WallStSmart

Evotec SE ADR (EVO)vsZoetis Inc (ZTS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Zoetis Inc generates 1222% more annual revenue ($9.49B vs $718.32M). ZTS leads profitability with a 26.4% profit margin vs -25.2%. EVO appears more attractively valued with a PEG of 1.42. ZTS earns a higher WallStSmart Score of 56/100 (C).

EVO

Hold

42

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.0Quality: 5.5
Piotroski: 5/9Altman Z: 0.38

ZTS

Buy

56

out of 100

Grade: C

Growth: 3.3Profit: 9.5Value: 5.3Quality: 6.5
Piotroski: 4/9Altman Z: 3.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EVOUndervalued (+89.5%)

Margin of Safety

+89.5%

Fair Value

$33.26

Current Price

$1.32

$31.94 discount

UndervaluedFair: $33.26Overvalued
ZTSUndervalued (+11.0%)

Margin of Safety

+11.0%

Fair Value

$144.57

Current Price

$79.11

$65.46 discount

UndervaluedFair: $144.57Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVO1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

ZTS5 strengths · Avg: 9.4/10
Return on EquityProfitability
75.3%10/10

Every $100 of equity generates 75 in profit

Operating MarginProfitability
38.2%10/10

Strong operational efficiency at 38.2%

Altman Z-ScoreHealth
3.1410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
26.4%9/10

Keeps 26 of every $100 in revenue as profit

P/E RatioValuation
14.0x8/10

Attractively priced relative to earnings

Areas to Watch

EVO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$600.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-28.6%2/10

ROE of -28.6% — below average capital efficiency

ZTS4 concerns · Avg: 2.5/10
Price/BookValuation
9.8x4/10

Trading at 9.8x book value

PEG RatioValuation
14.782/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.3%2/10

Revenue declined 1.3%

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : EVO

The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bull Case : ZTS

The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 26.4% and operating margin at 38.2%.

Bear Case : EVO

The primary concerns for EVO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : ZTS

The primary concerns for ZTS are Price/Book, PEG Ratio, Revenue Growth. Debt-to-equity of 2.80 is elevated, increasing financial risk.

Key Dynamics to Monitor

EVO profiles as a turnaround stock while ZTS is a declining play — different risk/reward profiles.

EVO carries more volatility with a beta of 1.31 — expect wider price swings.

EVO is growing revenue faster at 0.6% — sustainability is the question.

ZTS generates stronger free cash flow (717M), providing more financial flexibility.

Bottom Line

ZTS scores higher overall (56/100 vs 42/100), backed by strong 26.4% margins. EVO offers better value entry with a 89.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evotec SE ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.

Zoetis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Visit Website →

Want to dig deeper into these stocks?